Supreme Court hints at ruling in case over generics' use of skinny-label drugs

Supreme Court justices have offered preliminary signals about how they may decide a contentious lawsuit that could reshape the way generic drug makers market products with "skinny labels".

The case centers on whether generics can omit certain patented indications from their labeling while still selling the same molecule, a practice that has drawn criticism from brand-name manufacturers but is defended by generics as a way to avoid infringement.

The Court is set to hear final arguments later this term, and its forthcoming decision is expected to have significant implications for the pharmaceutical industry's patent strategy and market competition.